A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Inclusion Criteria:

1. Fully understand and voluntarily sign an informed consent form, willing and able tofollow the study process;

2. Age range is 18-75 years old (inclusive);

3. Pancreatic cancer confirmed by histology or cytology;

4. Stage IV metastasis Pancreatic cancer patients;

5. Have not received previous systematic anti-tumor treatment in the stage ofmetastatic pancreatic cancer;

6. According to RECIST 1.1, there is at least one measurable lesion;

7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;

8. Expected survival time ≥ 12 weeks;

Exclusion Criteria:

1. Use of systematic anti-tumor therapy within 4 weeks prior to the first dose；

2. Presence of other malignancies in the past 3 years;

3. Received major surgical surgery within 60 days before the first dose;

4. Have received any surgery or invasive treatment within 4 weeks before the first useof the drug;

5. Received palliative radiotherapy within 1 week before the first dose; receivedradical radiotherapy within 4 weeks before the first dose;

6. Any known allergy to surufatinib or its components, camrelizumab, nab-paclitaxel, orgemcitabine;

7. Received inducers or inhibitors of cytochrome P450 (CYP) 3A and CYP2C8 within 2weeks or 5 half-lives (whichever is longer) before the first dose;

8. Use of immunosuppressive drugs within 4 weeks before first dose;

9. Known history of clinically significant liver disease, including active viralhepatitis infection or other active hepatitis or clinically significant moderate tosevere cirrhosis;

10. Patients who currently have hypertension that cannot be controlled by medication;